The effect of the COVID-19 vaccination campaign on 250 cities in Israel

A recent study posted to the Research Square* preprint server and under consideration at BMC Infectious Diseases assessed the impact of coronavirus disease 2019 (COVID-19) vaccines on unvaccinated populations and analyzed the various vaccination policies in Israel.

Study: BNT162b2 mRNA Vaccinations in Israel: Understanding The Impact and Improving The Vaccination Policies by Redefining The Immunized Population. Image Credit: Gil Cohen Magen/Shutterstock
Study: BNT162b2 mRNA Vaccinations in Israel: Understanding The Impact and Improving The Vaccination Policies by Redefining The Immunized Population. Image Credit: Gil Cohen Magen/Shutterstock

*Important notice: Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Background

Various surveys have reported a stark decrease in new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Israel after 48% of its population was immunized against COVID-19. Understanding the parameters and variables that affected this decline in positive cases is important to formulate more effective COVID-19 policies.

About the study

The present observational study used daily demographics of SARS-CoV-2 cases and the economic data from 250 Israeli cities to investigate the impact of vaccination on unvaccinated populations. The researchers also studied the shift from the transition phase to the community-immunity phase observed in this country.

The team collected demographic data, including individual identification numbers, age, geographic area, date of polymerase chain reaction (PCR) test for COVID-19-diagnosis and test result, time of hospitalization, the worst hospital event, and COVID-19 outcome. Also, they obtained vaccination-related data like the number of vaccinations administered per day for different age groups and geographical areas. Additionally, data like the median age of a city population and the number of people belonging to each age group were collected.

The study defined two groups of populations, including the total population in a city and the populations susceptible to COVID-19 infections like the unvaccinated individuals and recovered COVID-19 patients. Furthermore, two important factors were also defined, namely the hospitalization impact factor and the positive impact factor. 

An extended framework of the susceptible-exposed-infectious-removed (SEIR+) model was used to simulate COVID-19 transmission in Israel and the impact of vaccination policies on this spread. In this model, each person is represented by one out of the following range of states: susceptible (S), exposed (E), infected but pre-symptomatic (Ipre), infected and asymptomatic (Iasym), infected and symptomatic (Isym), recovered (R), hospitalized (H), fatal (F), quarantined and susceptible (Qs), quarantined and exposed (QE), quarantined and pre-symptomatic (Qpre), quarantined and asymptomatic (Qasym), quarantined and symptomatic (Qsym), and quarantined and recovered (QR). The transitions between each state were assessed from the known probabilities of COVID-19 in Israel.  

The study also simulated vaccination policies having different vaccination rates. For each vaccination rate, four vaccination policies were simulated prioritizing the vaccination of:

1) younger populations,

2) older individuals,

3) people aged over 60 years, and

4) individuals aged between 16 and 35 years and then the rest of the populations; the last policy equally distributed vaccinations among all age groups. 

Results

The study results showed that from March 2020 and January 2021, a significant number of COVID-19-positive cases were observed in three SARS-CoV-2 infection waves. Also, an increase in cases was found in each subsequent wave. It was noted that when the vaccinations were first administered to the at-risk populations, there was a significant increase in the number of cases in the unvaccinated individuals, indicating the beginning of the transition phase. However, when 48% of the total population was vaccinated or COVID-19-recovered, a remarkable reduction in the number of cases was found across all the ages, suggesting the onset of the community-immunity phase.

The positive impact factor of the young population in comparison to the entire population (impactp−tot) and the susceptible population (impactp−sus) was evaluated. The impactp−tot of 0.6 observed before the onset of vaccinations indicated that the positive ratio of the younger population was 60% as compared to the entire population. The impactp−tot reached 1.3 after the vaccinations started, which suggested that a higher number of unvaccinated individuals were infected.

The study noted that cities with populations of a lesser median age exhibited a reduction in new SARS-CoV-2 infections even when a lower percentage of total individuals were vaccinated as compared to the other cities. Furthermore, the entire country of Israel, having a median age of 30.5 years, had a similar decrease in new positive cases when 50% of the country’s population was vaccinated.

The simulation of four vaccination policies showed that the prioritization of vaccine administration and vaccination rate of a region play a significant role in the number of COVID-19 cases and related hospitalizations. The present model showed that simultaneously vaccinating individuals of all age groups is the most efficient vaccination policy against COVID-19.       

Conclusion

The study findings showed that the age structure of a country plays a vital role in its COVID-19 vaccination policies. The study also highlighted the need to implement measures towards establishing community immunity across all populations. The researchers believed that this study can serve as a foundation for other countries for the development of effective COVID-19 policies.

*Important notice: Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Bhavana Kunkalikar

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kunkalikar, Bhavana. (2022, March 22). The effect of the COVID-19 vaccination campaign on 250 cities in Israel. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20220322/The-effect-of-the-COVID-19-vaccination-campaign-on-250-cities-in-Israel.aspx.

  • MLA

    Kunkalikar, Bhavana. "The effect of the COVID-19 vaccination campaign on 250 cities in Israel". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20220322/The-effect-of-the-COVID-19-vaccination-campaign-on-250-cities-in-Israel.aspx>.

  • Chicago

    Kunkalikar, Bhavana. "The effect of the COVID-19 vaccination campaign on 250 cities in Israel". News-Medical. https://www.news-medical.net/news/20220322/The-effect-of-the-COVID-19-vaccination-campaign-on-250-cities-in-Israel.aspx. (accessed November 22, 2024).

  • Harvard

    Kunkalikar, Bhavana. 2022. The effect of the COVID-19 vaccination campaign on 250 cities in Israel. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20220322/The-effect-of-the-COVID-19-vaccination-campaign-on-250-cities-in-Israel.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients